NCT03996330

Brief Summary

Pneumonia, a serious infection of the lungs, is a common reason for Intensive Care Unit (ICU) admission. It may also develop as a significant complication of being on a mechanical ventilator. Although the clinical diagnosis is generally straight-forward to make, determining which organism is causing the infection (pathogen) presents a much greater challenge. Existing detection of pathogens relies on growing the organism under specific conditions in a microbiology laboratory. This process is slow, typically taking 48 to 72 hours, and is influenced by factors such as presence of antibiotics and the ease with which specific organisms can be grown. Conventional microbiology may only be positive less than 40% of cases of pneumonia and this means that patients are often treated with 'best guess' antibiotics. These antibiotics are generally broad spectrum, and risk the development of antibiotic resistance. Equally, organisms which are less commonly seen may not be covered by the initial antibiotic selection and may only be started once this organism is grown after 48 to 72 hours leading to delays in appropriate treatment. The aim of this study is to evaluate the performance of a new form of diagnostic test, using detection of pathogens by gene analysis rather than relying on growth. The investigators believe that this approach will be more rapid and more sensitive, and therefore likely to translate into more rapid and appropriate use of antibiotics.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 5, 2018

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

June 20, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 24, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 16, 2019

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 23, 2019

Completed
Last Updated

November 19, 2019

Status Verified

November 1, 2019

Enrollment Period

1.5 years

First QC Date

June 20, 2019

Last Update Submit

November 18, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Time to result relative to conventional microbial culture

    Comparison of the time to result returned to clinicians between the taqman array card and conventional microbial culture

    5 days

  • Diagnostic performance compared to conventional culture

    Comparison of sensitivity and negative predictive value of array card relative to conventional microbial culture

    5 days

Secondary Outcomes (2)

  • Number and nature of organisms detected on taq-man array and not detected by conventional culture

    5 days

  • Sensitivity of PCR from blood relative to bronchoalveolar lavage PCR

    24 hours

Interventions

taqman array cardDIAGNOSTIC_TEST

The array card contains multiple PCR reactions for microbial pathogens, extracted microbial nuclear material from lavage or blood is run on the card to detect pathogen specific sequences by polymerase chain reaction.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Mechanically ventilated patients in intensive care with suspected pneumonia, from community acquired, hospital acquired and ventilator-associated sources.

You may qualify if:

  • Age \>18
  • Mechanically ventilated
  • Treating clinician clinically suspects pneumonia and is planning to undertake diagnostic bronchoscopy and lavage

You may not qualify if:

  • Inability to gain advice from a personal or professional consultee. Where a patient has capacity, declining consent for the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cambridge University Hospitals NHS Foundation Trust

Cambridge, Cambs, CB2 0QQ, United Kingdom

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

broncho-alveolar lavage, plasma

MeSH Terms

Conditions

Pneumonia

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Vilas Navapurkar, MB ChB

    Cambridge University Hospitals NHS Foundation Trust

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Research Associate and Honorary Consultant

Study Record Dates

First Submitted

June 20, 2019

First Posted

June 24, 2019

Study Start

February 5, 2018

Primary Completion

August 16, 2019

Study Completion

August 23, 2019

Last Updated

November 19, 2019

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will not share

Locations